Stress & Mood

Also known as: TP-7, Selank Spray

Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro, 750 Da molecular weight) developed in the 1990s at the Institute of Molecular Genetics of the Russian Academy of Sciences as a synthetic analog of tuftsin — an immunomodulatory tetrapeptide (Thr-Lys-Pro-Arg) that is naturally cleaved from the Fc region of immunoglobulin G. The original tuftsin molecule has well-documented immunomodulatory and neurotropic effects but is rapidly degraded by peptidases in plasma, limiting its therapeutic utility. Selank adds a Pro-Gly-Pro tail to the tuftsin sequence, which confers resistance to enzymatic degradation while preserving pharmacological activity. In Russia, Selank has been approved since 2004 for the treatment of generalized anxiety disorder (GAD) and is available by prescription at pharmacies across the Russian Federation and several neighboring countries. It is marketed as a 0.15% intranasal solution under the brand name "Selank" (╨í╨╡╨╗╨░╨╜╨║) by Peptogen, a Moscow-based pharmaceutical company. In Western markets, Selank has never been submitted for FDA, EMA, or other major regulatory approval — not because of unfavorable data, but because the commercial pharmaceutical industry has no mechanism to profit from a peptide with an expired patent and no Western development sponsor. As a result, Selank circulates in the biohacking and peptide-curious community primarily as a "research chemical" through specialty peptide suppliers, where it is sold in intranasal spray or injectable formulations. The pharmacological profile of Selank is distinctive among anxiolytics. Unlike benzodiazepines, it does NOT cause sedation, cognitive dulling, tolerance, dependence, or withdrawal. Unlike SSRIs, it has rapid onset (within 30-60 minutes of intranasal administration) and effects that outlast plasma presence. Unlike buspirone, it does not require weeks of chronic dosing to manifest effects. The compound appears to work through modulation of multiple neurotransmitter systems simultaneously — GABAergic, serotonergic, dopaminergic, and endogenous opioid — producing what the Russian clinical literature describes as an "anxiolytic + nootropic" profile: the user feels calmer but also more mentally engaged, not sedated. This unusual combination has driven substantial interest in Western biohacking circles as an alternative or adjunct to conventional anxiety pharmacology. Selank has been studied in Russian clinical populations for over two decades with a consistent efficacy and safety pattern across roughly 30-50 published clinical papers. The evidence base is real but has important limitations: most trials are Russian-language, published in Russian journals, with small sample sizes (often 30-100 patients), and use Russian psychiatric rating scales rather than the validated Western instruments (GAD-7, HAM-A, Beck Anxiety Inventory) that would facilitate cross-validation. Western meta-analyses and systematic reviews are essentially nonexistent. The Russian regulatory approval is real and meaningful — Russian drug regulation, while different from FDA standards, does require efficacy and safety evidence — but it does not automatically translate to confidence in Western evidence-based medicine frameworks. For the biohacking community, Selank's appeal is the combination of (1) rapid-acting anxiolysis without sedation, (2) cognitive enhancement rather than dulling, (3) favorable safety profile across decades of Russian use, (4) non-addictive, non-dependence-producing pharmacology, and (5) intranasal delivery that is simple and needle-free. Its limitations are (1) thin Western evidence base, (2) variable quality from research chemical suppliers, (3) lack of FDA regulation or oversight, (4) modest effect magnitude in some users relative to expectations, and (5) cost relative to generic anxiety pharmacology. This entry covers the pharmacology, clinical evidence, practical use considerations, and honest framing of the evidence gaps. Cross-reference with Semax, DSIP, and Epithalon for a complete picture of the Russian research peptide landscape.

Also known as: NASA-Selank, N-Acetyl Selank

Acetylated form of Selank peptide with enhanced bioavailability, commonly used as a nasal spray for anxiolytic and nootropic effects.

Also known as: ACTH 4-10, BDNF Spray, BDNF, Flow Spray

Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro, MEHFPGP, 813 Da molecular weight) developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in the 1980s. The compound is derived from ACTH(4-10) — the 4-10 amino acid fragment of adrenocorticotropic hormone — with the addition of a Pro-Gly-Pro C-terminal tail that confers resistance to enzymatic degradation while preserving neurotropic activity. Critically, Semax retains the cognitive, neurotrophic, and neuroprotective effects of its ACTH parent while completely lacking the adrenal-stimulating hormonal activity. In other words, Semax works on the brain without activating the HPA axis or affecting cortisol production — a therapeutically ideal profile. Semax was patented in 1982 by Russian researchers and achieved regulatory approval in the Russian Federation in 2000, where it is prescribed at pharmacies for cerebrovascular disorders (ischemic stroke recovery), optic nerve disorders, minimal brain dysfunction in children (ADHD-like presentations), asthenia, and various cognitive complaints. It is available in two commercial strengths: 0.1% intranasal solution for cognitive-nootropic indications and 1% intranasal solution for stroke recovery and neurological deficits. In Western markets, Semax has never been submitted for FDA, EMA, or other major regulatory approval — a pattern common to Russian neuropeptides that lack patent protection and Western pharmaceutical sponsors. It circulates in US and European biohacking communities through research chemical peptide suppliers and is considered one of the most potent, best-tolerated nootropic compounds available. The pharmacology of Semax is genuinely notable and spans multiple neurological domains. At the molecular level, Semax elevates BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor) expression in the brain, promotes dopaminergic and serotonergic signaling, potentiates endogenous enkephalin activity, and upregulates expression of neuroprotective genes. At the clinical level, it produces cognitive enhancement (attention, memory, executive function), mood elevation, stress tolerance, neuroprotection during ischemia, and accelerated recovery from neurological injury. Russian clinical trials in acute ischemic stroke — the best-documented Semax indication — show meaningful improvements in functional recovery when Semax is administered within 6-24 hours of stroke onset, likely through direct neuroprotection plus enhanced neurogenesis during recovery. The stroke literature is the only domain where Semax has truly rigorous clinical trial evidence (Gusev et al., 2005). In the biohacking and cognitive enhancement community, Semax has achieved a reputation as the "premier Russian nootropic" — often positioned alongside Selank, Noopept, Modafinil, and racetams in the advanced cognitive stack. Users typically report improvements in focus, working memory, verbal fluency, motivation, stress tolerance, and overall cognitive throughput. The effects are often described as "clean" — producing alertness and engagement without the jitters of stimulants, without the emotional blunting of SSRIs, and without the sedation of anxiolytics. Dose-response is relatively modest (300-900 mcg daily typical), onset is rapid (15-30 minutes after intranasal administration), and effects last several hours per dose. Chronic use over weeks produces accumulating cognitive and mood benefits that appear to outlast plasma presence. This entry covers Semax pharmacology, the genuinely rigorous Russian stroke evidence base, the more speculative cognitive enhancement applications, protocol considerations, and safety profile. It should be read as an educational reference — Semax is not FDA-approved, is distributed through gray-market channels with variable quality, and anyone considering use should obtain reliable product, start conservatively, and have realistic expectations. Cross-reference with Selank, DSIP, and Epithalon for Russian peptide context, and with Noopept, Piracetam, and Modafinil for broader nootropic comparisons.

Also known as: Delta Sleep, Hypnos

Delta sleep-inducing peptide (DSIP) is a nonapeptide — a 9-amino-acid neuropeptide with sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (WAGGDASGE, 848 Da molecular weight) — first isolated in 1977 from the cerebral venous blood of rabbits subjected to electrical stimulation of the intralaminar thalamus, a brain region involved in sleep regulation. The original Swiss investigators, Schoenenberger and Monnier at the University of Basel, named the peptide for the prominent delta-wave EEG activity they observed in recipient rabbits after intracerebroventricular injection of the purified fraction, implying a role in slow-wave (deep) sleep generation. The name, however, has proven misleading. Four decades of follow-up research have produced a pharmacological profile that is substantially more complex than "sleep peptide" — and, depending on how generously you interpret the human clinical data, somewhat less impressive than the name suggests. DSIP does not reliably produce the dramatic delta-wave surges in humans that it appeared to produce in the original rabbit EEG studies. It does, however, demonstrate real effects on sleep architecture, stress response, pain modulation, and possibly mood regulation, and it has been studied (primarily in Russian, Eastern European, and Japanese clinical literature from the 1980s-1990s) for chronic insomnia, chronic pain syndromes, alcohol and opioid withdrawal, depression, and as an adjunct to conventional sleep and anxiolytic medications. Despite 40+ years of research, DSIP has never been approved by the FDA, EMA, or any major regulatory agency for any indication. It circulates today almost exclusively through the research chemical peptide market, where it is sold as subcutaneous injection vials, nasal spray formulations, and occasionally as sublingual preparations. Users report highly variable effects — some describe profound sleep improvements from a single bedtime injection, others notice nothing at all, and a subset report vivid dreams or morning "grogginess" that can last into the next day. The compound's reputation in the biohacking community is of a "safe, non-addictive, mild-effect sleep aid" positioned as a cleaner alternative to benzodiazepines, z-drugs (zolpidem, eszopiclone), and chronic melatonin. Whether it actually deserves that reputation depends substantially on what clinical claims you are willing to accept on thin evidence. This entry covers what is genuinely established about DSIP pharmacology, what the clinical trial record actually shows (versus what marketing claims), how it is used in practice by peptide practitioners, safety considerations, and honest framing of the evidence gaps. It should be read as an educational reference, not a prescription — DSIP is not FDA-approved, is distributed through gray-market channels of variable quality, and any serious use decision should involve a qualified physician familiar with research peptides, appropriate sleep-hygiene tuning first, and realistic expectations. Cross-reference this page with Semax, Selank, and Epitalon for a complete picture of the Russian-origin "research peptide" landscape, and with BPC-157 and Tesamorelin for more thoroughly characterized peptide therapeutics.

Also known as: β-phenyl-γ-aminobutyric acid, beta-phenyl-GABA, Noofen, Anvifen, Fenibut, Фенибут, phenigamma, phenybut

Phenibut is the common Western name for β-phenyl-γ-aminobutyric acid (beta-phenyl-GABA; Russian trade names Phenibut/Фенибут, Noofen, Anvifen), a Soviet-era anxiolytic and nootropic developed in the 1960s at the Herzen State Pedagogical Institute in Leningrad under Vsevolod Vasilievich Perekalin. Structurally, it is the GABA molecule with a phenyl ring attached to the β-carbon — a modification that dramatically increases lipophilicity and allows the compound to cross the blood-brain barrier (unlike GABA itself, which does not meaningfully penetrate the CNS after oral dosing). In the Soviet Union and, later, the Russian Federation and several CIS states, phenibut is a prescription medication approved for asthenia, generalised anxiety, pre-operative anxiety, insomnia related to anxiety, post-traumatic stress reactions, vestibular disorders, motion sickness, stuttering, and several pediatric indications. It was reportedly included in the Soviet cosmonaut medical kit in the 1970s — a detail endlessly repeated in online marketing that is often used to imply safety and efficacy, though the actual context (managing acute stress in a highly selected, closely monitored population) is quite different from the way most contemporary users take it. Outside of Russia and the CIS, phenibut has no regulatory approval. It is not a recognised medicine in the United States, the United Kingdom, the European Union, Canada, or Australia, and it is not listed on any Western pharmacopoeia. Its legal status is fragmented: Australia classifies it as a Schedule 9 prohibited substance; Hungary and several European countries treat it as a controlled substance; Lithuania, Latvia, Finland, and Italy have placed it under medicines regulation; the United Kingdom controls it under the Psychoactive Substances Act 2016. In the United States, phenibut is unscheduled at the federal level but the FDA has formally warned that it does not meet the statutory definition of a dietary supplement under DSHEA, issuing warning letters to multiple vendors in 2019 and 2020 for marketing phenibut-containing products. Despite this, it has been sold online as a nootropic powder or capsule under names like "Phenibut HCl" or "Phenibut FAA" (free amino acid form) for over a decade, often at doses and in contexts that Russian prescribers would consider grossly inappropriate. The core pharmacology of phenibut is that it is a GABA-B receptor agonist — in the same receptor family as baclofen and the recreational drug gamma-hydroxybutyrate (GHB) — with weaker activity at GABA-A receptors and some binding to voltage-gated α2δ calcium channels similar to pregabalin and gabapentin. This combination produces anxiolysis, mild sedation, euphoria at higher doses, and — critically — the capacity to produce severe physical dependence and withdrawal after repeated use. Phenibut's withdrawal syndrome closely resembles combined benzodiazepine and alcohol withdrawal, with insomnia, severe rebound anxiety, tremor, perceptual disturbances, and in case reports, seizures and delirium. The withdrawal risk is the single most important thing any prospective user needs to understand, and it is the primary reason phenibut appears on harm-reduction lists and clinician warning pages. The Western nootropic community's relationship with phenibut has shifted over the past decade. Early online discussion (roughly 2010-2016) treated it as a relatively benign "smart drug" or occasional anxiolytic, often with inadequate attention to tolerance and withdrawal. Over time — as case reports of severe withdrawal accumulated on PubMed (PMID 28498611, PMID 31524352, PMID 29870003, PMID 30339766, among others) and as poison control centres in Australia, Finland, and the United States began reporting regular phenibut-related calls — the community has become substantially more cautious. Responsible nootropic resources now categorise phenibut as a compound with legitimate short-term use cases (occasional social anxiety, jet-lag-related anxiety, pre-exam stress) but a narrow therapeutic window and a steep risk curve that escalates rapidly with frequency of use. Anyone considering phenibut needs to read the contraindications and protocol sections below before the description. For a more rigorously evidence-based approach to anxiety, Western first-line treatments include SSRIs (sertraline, escitalopram), SNRIs (venlafaxine, duloxetine), and cognitive-behavioural therapy, all with substantially more strong trial data than phenibut. For acute situational anxiety in settings where a prescription is available, a single dose of propranolol or a short-acting benzodiazepine under medical supervision carries its own risks but is a better-characterised option. For a stimulant-free anxiolytic with a much lower dependence profile, see l-theanine — it lacks phenibut's potency but does not produce meaningful tolerance or withdrawal. For Russian-origin nootropics with similar geographic provenance but a very different safety profile, see selank and semax, which are peptides without the dependence liability. Phenibut is not in the same safety category as any of those compounds and should not be substituted for them without understanding the differences.

Also known as: Charisma

Active compound from kava for relaxation and sleep support.

Also known as: Withania somnifera, Indian Ginseng, Winter Cherry, KSM-66, Sensoril, Shoden

Ashwagandha (Withania somnifera, also called "Indian ginseng" and "winter cherry") is the most studied and most clinically validated herbal adaptogen in the contemporary supplement market. It is the botanical anchor of Ayurvedic medicine — the indigenous medical tradition of the Indian subcontinent — where its Sanskrit name "ashwagandha" ("smell of horse") refers to the distinctive odor of the fresh root and alludes to the traditional belief that the root confers the strength of a horse. Ashwagandha has been used medicinally for over 3,000 years in Ayurvedic practice as a rasayana (rejuvenative), traditionally prescribed for fatigue, weakness, reproductive concerns, chronic inflammation, joint pain, and general vitality. In the past 15 years, modern clinical research has confirmed and expanded many of these traditional uses, producing one of the strongest randomized controlled trial evidence bases in the entire botanical medicine space — covering stress, anxiety, sleep, testosterone, muscle strength, cognitive function, and metabolic health. The pharmacologically active constituents of ashwagandha are a family of steroidal lactones called withanolides, structurally similar to both plant and animal sterols. The most studied withanolides are withaferin A (the most pharmacologically potent, concentrated in leaves), withanolide A, withanolide D, withanolide E, withanoside IV and VI, and the sitoindosides (VII–X). Standardized ashwagandha extracts are characterized by their total withanolide content (typically 1.5–10% by weight) and by their specific withaferin A content (which varies from trace amounts in root-only extracts to 0.5–2% in leaf-containing extracts). Two branded extracts dominate the clinical literature and commercial market: KSM-66 (Ixoreal Biomed, India — root-only extract standardized to at least 5% withanolides with very low withaferin A), and Sensoril (Natreon, India — root-plus-leaf extract standardized to at least 10% withanolides with 32% higher withaferin A content). These two branded extracts have materially different pharmacologic profiles and clinical use cases: KSM-66 has been studied predominantly for stress, cognitive, reproductive, and athletic performance indications; Sensoril has been studied for sleep, anxiety, and general adaptogen applications where the faster onset attributable to withaferin A is desired. BodyHackGuide covers ashwagandha as the first-line adaptogen for the stress-sleep-recovery axis, alongside companion agents like rhodiola rosea (a stimulating adaptogen with better acute-cognitive effects), bacopa monnieri (cognitive and memory focus), l-theanine (acute relaxation without sedation), magnesium glycinate (mineral cofactor for stress and sleep), and gotu kola (circulatory and cognitive Ayurvedic companion). Within this framework, ashwagandha is the anchor for cortisol normalization, chronic stress adaptation, sleep quality improvement, and recovery from physical and mental exertion. It is particularly valuable for users managing the "wired and tired" pattern of chronic sympathetic overactivation — elevated evening cortisol, poor sleep onset or depth, morning fatigue despite adequate sleep hours, difficulty winding down after work, and the sense of running on adrenaline rather than sustained energy. The contemporary clinical evidence base for ashwagandha includes more than 30 randomized controlled trials with mostly positive findings across four main indication clusters. First, stress and anxiety: Chandrasekhar 2012 (PMID 23439798) — the classic RCT of KSM-66 300 mg BID in 64 chronically stressed adults over 60 days, showing 28% reduction in serum cortisol, 44% reduction in perceived stress scale (PSS), and significant reductions in State-Trait Anxiety Inventory and General Health Questionnaire scores. Salve 2019 (PMID 32082747), Lopresti 2019 (PMID 31517876), and multiple subsequent RCTs have replicated the cortisol-reducing and stress-relieving effects. Second, sleep: Langade 2019 (PMID 31728244) — 600 mg/day of ashwagandha root extract in 80 non-clinical insomnia subjects over 10 weeks, showing significant improvements in sleep onset latency, total sleep time, and sleep efficiency on actigraphy, with parallel improvements in anxiety. Third, testosterone and reproductive health: Ambiye 2013 (PMID 24371462) in oligospermic males showed 17% testosterone elevation and improved sperm parameters; Lopresti 2019 Am J Mens Health (PMID 30854916) in aging overweight males showed 14% testosterone elevation and DHEA-S increase over 16 weeks; Chauhan 2022 PMID 35873404 in healthy adult males showed improvements in testosterone, sperm concentration, and vitality markers. Fourth, muscle strength and athletic performance: Wankhede 2015 (PMID 26609282) in resistance-training men showed significantly greater strength gains on bench press and leg extension, greater muscle mass gains, and reduced exercise-induced muscle damage markers with KSM-66 600 mg/day over 8 weeks compared to placebo; subsequent trials have confirmed the strength and body-composition effects, with more modest signals on endurance (Choudhary 2015 PMID 26730141). Beyond these four clusters, ashwagandha has emerging or supportive evidence in: cognitive function in aging and mild cognitive impairment (Choudhary 2017, Ng 2020, several small trials showing modest improvements in memory, processing speed, and executive function); metabolic health (modest improvements in fasting glucose, HbA1c, HOMA-IR, and lipid profile in small trials); thyroid function (trials in subclinical hypothyroidism showing mild TSH reduction and T3/T4 elevation — a double-edged effect that can help or harm depending on thyroid status); immune function (increased white blood cell count and improved mucosal immunity in small trials); and bipolar disorder and schizophrenia (small adjunct RCTs showing modest signals, though these are specialist-care contexts rather than self-directed supplement use). Commercially, ashwagandha is among the fastest-growing supplement ingredients of the past decade. Branded KSM-66 and Sensoril extracts dominate the quality tier of the market, appearing in products from Thorne, Life Extension, Jarrow Formulas, NOW Foods, Pure Encapsulations, Designs for Health, Himalaya, and dozens of sports nutrition and wellness brands. Typical formulations: KSM-66 at 600 mg/day (300 mg BID or as a single evening dose), Sensoril at 125–250 mg/day (usually single daily dose), or generic standardized ashwagandha at 300–600 mg/day of a 5% withanolide extract. Quality varies substantially: non-standardized "ashwagandha root powder" bulk capsules bear little resemblance to the clinical-trial standardized extracts and should generally be avoided for therapeutic intent. Cost for branded extracts: roughly $15–30 per month depending on dose and retailer. Ashwagandha is best understood as a foundational daily-use adaptogen for modern stress physiology. It is not a sedative (it does not cause drowsiness during the day), not a stimulant (it does not produce the alertness of caffeine or rhodiola), and not an acute anxiolytic (it does not produce benzodiazepine-like rapid anxiety reduction). It is, instead, a slow-acting HPA-axis modulator that reduces baseline cortisol, improves stress-response resilience, supports sleep quality, and enables recovery from sustained physical and mental exertion over weeks to months of consistent use. For BodyHackGuide users managing chronic stress, sleep disruption, recovery demands from training, or the generalized symptoms of hyper-aroused modern life, ashwagandha is the single most defensible adaptogen choice with the strongest clinical evidence base and a favorable safety profile across most populations.

Also known as: gamma-glutamylethylamide, N-ethyl-L-glutamine, γ-L-glutamylethylamide, Suntheanine, Theanine

L-Theanine is a non-proteinogenic amino acid found almost exclusively in tea (Camellia sinensis) and a handful of edible mushrooms, and it has become the single most widely-used calm-focus nootropic in the modern supplement market — both on its own at 100-400mg doses and, even more prominently, as the classic 1:1 or 2:1 pair with caffeine that defines the "calm-focus" experiential signature of green tea and of virtually every serious nootropic stack. Chemically L-theanine is γ-glutamylethylamide (N-ethyl-L-glutamine), a structural analog of the excitatory neurotransmitter glutamate and its inhibitory cousin GABA — close enough to both to interact with their transporters and, at high doses, their receptors, but distinct enough to produce a characteristic combination of reduced sympathetic arousal, mildly enhanced alpha-wave EEG activity, and preserved or modestly improved attention that the literature has consistently tied to its single signature phrase: "relaxed alertness." The modern L-theanine literature traces back to Japanese tea-chemistry research in the 1950s — theanine was first isolated from green tea by Sakato in 1949 — but its Western nootropic adoption is much more recent, anchored by three key human studies: Kobayashi et al. 1998 (Japanese EEG study, alpha-wave elevation at 50-200mg oral doses), Haskell et al. 2008 (Biological Psychology PMID: 18006208), which showed that 100mg L-theanine + 50mg caffeine produces faster attention-task reaction times and subjectively better mood than either compound alone, and Kimura et al. 2007 (Biological Psychology PMID: 16930802), which demonstrated that 200mg L-theanine reduces heart rate and salivary immunoglobulin A responses to an acute stress task — the cleanest human physiology demonstration of its anxiolytic effect. Supporting RCTs include Hidese et al. 2019 (Nutrients, 4-week 200mg/day for stress and sleep in healthy adults) and Lyon et al. 2011 (Alternative Medicine Review, 200mg BID improving sleep quality in boys with ADHD). Pharmacologically, L-theanine crosses the blood-brain barrier via the large neutral amino acid transporter (LAT1), reaching brain tissue within 30-60 minutes of an oral dose. It has a plasma half-life of roughly 1-3 hours in humans, with central nervous system exposure outlasting plasma, and it acts on multiple neurotransmitter systems simultaneously (glutamate, GABA, dopamine, serotonin, catecholamines) — but at physiologic supplement doses its effects on any single system are modest. It is a weak, broadly-acting modulator rather than a strong selective agent. This is why it does NOT cause sedation, dependence, tolerance, or rebound the way GABAergic sedatives (phenibut, benzodiazepines, Z-drugs) do — you can take 200mg daily for years without tolerance development. The largest user population is the caffeine-stack crowd — knowledge workers, students, coders, writers — taking 100-200mg caffeine daily for alertness and wanting to take the edge off the jitter without losing the focus boost. The canonical stack is 200mg caffeine + 200mg L-theanine taken together once in the morning. A second population uses it for acute stress (200mg, 30-60 minutes before a stressful event). A third cohort uses 400-600mg for schizophrenia-adjunctive anxiety based on the Ritsner 2011 data (PMID: 21208586). A fourth uses 200-400mg at bedtime for sleep quality, though the adult sleep evidence is weaker than the ADHD-boys data from Lyon 2011. Where L-theanine does NOT work: it is not a sedative, not a cognitive enhancer in isolation (the attention benefit shows up only when paired with caffeine), not a panic-attack abortive, not an SSRI substitute for clinical depression or GAD, and not equivalent to meditation or therapy for chronic anxiety. Safety profile stands out: FDA-GRAS since 2007 as Suntheanine®, rodent LD50 >5 g/kg (effectively unreachable at oral doses), decades of dietary human exposure through green tea, no dependence or withdrawal reported in any RCT. Side effects (mild headache, GI upset, dizziness at high doses) occur at placebo-comparable rates. The only meaningful practical cautions are possible additive hypotensive effect with blood-pressure medications and theoretical interaction with stimulant medications (though theanine + stimulant combinations are actually commonly used and well-tolerated). L-theanine pairs well with nearly everything. The caffeine pair is canonical. Ashwagandha is increasingly common for daytime anxiolysis. Magnesium glycinate or L-threonate pairs for evening use. Rhodiola rosea + L-theanine + caffeine is a strong "calm focus + adaptogen" stack. Avoid stacking with strong sedatives (benzodiazepines, high-dose kava, phenibut in naive users) — not because of a specific interaction but because the subjective synergy blunts the productive-calm signature L-theanine is typically used for. This is educational content and not medical advice; L-theanine is exceptionally safe for most healthy adults but blood-pressure medications, antipsychotics, and pregnancy/pediatric use warrant physician input before supplementation.

Also known as: Mg, Mg2+, Magnesium citrate, Magnesium glycinate, Magnesium bisglycinate, Magnesium malate, Magnesium taurate, Magnesium L-threonate, Magnesium oxide, Magnesium chloride, Magnesium sulfate, Magnesium orotate, Magnesium lactate, Epsom salt

Magnesium is the fourth most abundant cation in the human body and the second most abundant intracellular cation after potassium, with approximately 25 grams present in a typical adult—roughly 60% stored in bone, 27% in muscle, 6-7% in other soft tissues, and less than 1% in extracellular fluid including serum. Despite this substantial total-body load, magnesium deficiency is extraordinarily common in modern populations: national survey data from the United States (DiNicolantonio et al., PMID 29387438; Rosanoff et al., PMID 22365240) suggests that roughly half of adults consume below the estimated average requirement, and a meaningful fraction—perhaps 10-30% depending on the criterion used—show biochemical evidence of frank deficiency. The prevalence is even higher among patients with type 2 diabetes, alcohol use disorder, heart failure, chronic proton pump inhibitor users, loop/thiazide diuretic users, and elderly adults with reduced appetite or impaired intestinal absorption. Because serum magnesium (the most commonly ordered clinical test) measures only that <1% extracellular fraction and is tightly defended by bone mineral release and renal reabsorption even when cellular stores are depleted, normal serum magnesium does not rule out functional deficiency. Many researchers argue that the reference range itself is set too low, rooted in population distributions that already reflect widespread subclinical deficiency. Magnesium functions as a required cofactor for more than 600 enzymatic reactions (Gröber et al., PMID 26404370)—essentially every reaction involving ATP, because the bioactive form of ATP is the Mg-ATP complex and free ATP has negligible biological activity. This places magnesium at the center of energy metabolism, protein synthesis, DNA and RNA synthesis, oxidative phosphorylation, glucose utilization, and cellular electrolyte homeostasis. Beyond its cofactor roles, magnesium is a physiological calcium channel antagonist: it competes with calcium at voltage-gated calcium channels in smooth muscle, cardiac conducting tissue, and neurons, which explains its effects on vascular tone, cardiac rhythm, neuromuscular excitability, and neuronal signaling. Magnesium also voltage-gates the NMDA glutamate receptor in the central nervous system—one of the fundamental mechanisms of synaptic plasticity and learning, and a key point of regulation in pain signaling, seizure thresholds, and mood. Supplemental magnesium is among the most thoroughly studied nutrient interventions in clinical medicine. Randomized trials and meta-analyses demonstrate meaningful effects on blood pressure (Zhang et al., PMID 27402922), insulin sensitivity and glycemic control in type 2 diabetes (Guerrero-Romero, PMID 21127832; Rodríguez-Morán and Guerrero-Romero, PMID 12663588), migraine frequency (Peikert et al., PMID 8792038; Facchinetti et al., PMID 1860787; Mauskop review, PMID 29314056), sleep quality in older adults (Abbasi et al., PMID 23853635), leg cramps in late-pregnancy and general populations (mixed evidence), depression symptoms (Tarleton et al., PMID 28654669), and muscle performance. Observational evidence associates higher magnesium intake with lower all-cause mortality, lower cardiovascular disease incidence, lower stroke risk, lower risk of type 2 diabetes, and better bone mineral density. Magnesium is also a first-line intravenous intervention for preeclampsia/eclampsia (MgSO4), torsades de pointes, severe asthma exacerbation, and certain arrhythmias—uses that reflect strong hospital-setting evidence but are distinct from routine oral supplementation. Commercial magnesium supplements span a confusing landscape of salts—citrate, glycinate (also called bisglycinate), malate, taurate, L-threonate, oxide, chloride, sulfate, orotate, lactate, aspartate, carbonate, hydroxide—with meaningfully different bioavailability profiles, elemental magnesium content per gram, tolerability, and tissue-specific effects. Magnesium oxide, despite being the cheapest and most common in drugstore multivitamins, has poor bioavailability (perhaps 4% absorbed in some studies) and tends to produce diarrhea. Magnesium glycinate and bisglycinate are generally regarded as among the best-tolerated forms for doses above a few hundred milligrams, with smooth absorption and minimal GI effect. Magnesium L-threonate is the only form with clinical trial evidence for brain-penetrant effects on memory and cognition (Liu et al., PMID 25589719) and is marketed as Magtein. Magnesium taurate combines two cardioprotective minerals and is particularly favored for cardiovascular indications. Magnesium malate may benefit muscle energy metabolism via the malate-aspartate shuttle. The "best" form depends on the goal: sleep and general repletion favor glycinate or citrate; constipation relief favors citrate or oxide; migraine prophylaxis was studied mainly with citrate (600 mg trivalproate equivalents) or oxide; cognition research favors L-threonate; cardiovascular goals may favor taurate. For BodyHackGuide users, magnesium is a cornerstone of any rational supplementation stack. The cost-to-benefit ratio is exceptional: for a few dollars monthly, users correct a common subclinical deficiency and gain measurable improvements in sleep latency, stress resilience, bowel regularity, blood pressure, and exercise recovery. The safety margin is wide for healthy adults with normal renal function. Yet many users either take too little (100-200 mg oxide from a multivitamin, poorly absorbed, insufficient to raise cellular stores) or take the wrong form for their goal. This monograph addresses form selection, dose titration, timing, stacking, and the specific clinical scenarios where magnesium supplementation is best evidenced. For related foundational support, see /compound/vitamin-d (reciprocal activation with magnesium in converting 25(OH)D to 1,25(OH)2D), /compound/zinc (another ubiquitously deficient mineral), /compound/taurine (synergy in magnesium taurate), /compound/glycine (synergy in magnesium glycinate), and /compound/creatine (ATP-dependent metabolism where magnesium is the counter-ion).

Also known as: Magtein, L-Threonic Acid Magnesium Salt, MgT, Magnesium-L-Threonate, L-TAMS, Mg L-Threonate

Magnesium L-Threonate is a proprietary chelated form of magnesium in which the magnesium cation is bound to L-threonic acid — a metabolite of ascorbic acid (vitamin C) — forming the salt commonly marketed under the brand name Magtein. It was developed in the mid-2000s by researchers associated with MIT (notably Guosong Liu, then at the MIT Department of Brain and Cognitive Sciences) with the explicit goal of producing a magnesium compound that could meaningfully raise brain magnesium concentrations in a way that ordinary oral magnesium salts (oxide, citrate, glycinate, malate, chloride) have historically struggled to accomplish. The resulting molecule was commercialized through Magceutics and Neurocentria, and Magtein is now the dominant ingredient in cognition-oriented magnesium products marketed to consumers. The clinical rationale behind magnesium L-threonate rests on a specific biological problem: magnesium is a physiological NMDA glutamate receptor antagonist — a voltage-dependent blocker that sits in the NMDA channel pore and regulates excitatory neurotransmission — yet CNS magnesium concentrations are tightly defended and do not readily rise in response to oral supplementation with most common magnesium forms. Even substantial oral dosing of magnesium oxide or citrate (often 400mg elemental or more daily) may produce modest serum changes without corresponding cerebrospinal fluid (CSF) or brain extracellular magnesium elevation. This is not merely a theoretical concern — it implies that people using conventional magnesium supplements for cognitive, sleep, anxiety, or mood benefits may be relying partly on peripheral effects and on small central effects that are difficult to measure and potentially limited in magnitude. Slutsky et al. 2010 (Neuron PMID: 20152124) — the landmark MIT paper — demonstrated that L-threonate conjugation allows magnesium to raise brain magnesium concentrations in rats in a way that other forms did not, and that this elevation translated into upregulated synaptic density, enhanced LTP (long-term potentiation), and improved behavioral measures of learning and memory in aged animals. This rat paper remains the single most cited justification for preferring Magtein over other magnesium forms for cognitive applications. Translated human evidence is substantially thinner than the mechanistic rat data. Liu et al. 2016 (Journal of Alzheimer's Disease PMID: 26600199) — the only decent human RCT published as of this writing — enrolled 44 older adults (ages 50-70) with cognitive impairment and randomized them to 12 weeks of Magtein (1.5-2 grams/day providing approximately 144-192mg elemental magnesium) or placebo. The trial reported improvements on a composite cognitive score that the authors interpreted as a reduction in "brain age" by approximately 9 years. Results were favorable but the study was small, industry-sponsored (funded by Magceutics), and independent replication has been weak — a point that matters for a supplement marketed with confident claims about cognition, memory, and "brain age." Users and practitioners should weigh that single decent RCT carefully: it is the most promising human data we have, but one small industry-funded trial is not a strong evidence base for the specific cognitive claims routinely made about Magtein in consumer marketing. Subsequent small trials have examined anxiety, sleep, and subjective cognitive symptoms with mixed and generally modest findings. Why people actually take magnesium L-threonate in practice usually comes down to a few overlapping use cases: (1) cognitive support — particularly older adults or people concerned about age-related cognitive decline, based on Slutsky 2010 and Liu 2016; (2) sleep — evening dosing is commonly reported to improve subjective sleep quality, though this overlap substantially with non-specific benefits of magnesium repletion that are equally achievable with much cheaper Magnesium glycinate; (3) anxiety — systematic reviews of magnesium and anxiety (Pickering 2020 PMID: 32210180) pool across many forms and find modest positive effects, but threonate-specific anxiety data are limited; (4) general magnesium repletion with a cognition halo — some users take Magtein as their primary magnesium source while hoping to capture both general repletion and specific CNS effects. A practical point up front: Magtein delivers relatively little elemental magnesium per dose. The typical 1.5-2g/day Magtein dose provides ~144-192mg elemental magnesium — considerably less than a standard magnesium glycinate dose (200-400mg elemental at a fraction of the cost). For systemic magnesium repletion (muscle cramps, constipation, blood pressure, general wellness), glycinate is equivalent or superior and substantially cheaper. Magtein's proposed advantage is narrowly about CNS magnesium elevation for cognitive applications. Users often combine Magtein with another cheaper magnesium form to hit general elemental targets; relying on Magtein alone for both CNS and general repletion rarely pencils out. The commercial landscape also warrants attention. "Magnesium threonate" products fall into two broad categories: Magtein-branded (certified through Magceutics/Neurocentria licensing, defined L-isomer specifications, third-party testing) and generic "magnesium threonate" (uncertain L-isomer purity, not studied in the published clinical research). The published evidence applies specifically to Magtein; this distinction is often glossed over in consumer marketing and price differences typically reflect it. See also Magnesium, Lion's Mane, Creatine, Citicoline, Acetyl-L-Carnitine, Bacopa, Phosphatidylserine, and Fisetin for adjacent cognitive-support and magnesium-related compounds commonly used in nootropic stacks. This is educational content and not medical advice — magnesium supplementation is generally safe but clinical applications (particularly in renal impairment, in children, or with drug-interacting medications) warrant physician-level guidance.

Also known as: Aminoacetic acid, Glycocoll, G, Gly, L-Glycine, Glycin, Aminoessigsäure

Glycine is the simplest amino acid—a single hydrogen atom replacing the typical side chain found in other proteinogenic amino acids—yet it performs an wide range of biological functions. Despite being classified as "non-essential" because humans can synthesize it endogenously from serine and other precursors, mounting evidence suggests glycine is conditionally essential: the synthetic capacity of human tissues falls short of daily functional demands, particularly during periods of stress, injury, aging, and rapid growth. This gap between synthesis and requirement makes dietary glycine practically important, and supplemental glycine emerges as one of the most evidence-based, low-cost, and versatile compounds in the foundational nutrition category. Glycine's biological roles span multiple major categories. It is the most abundant amino acid in collagen, comprising approximately one-third of collagen's amino acid residues (every third residue in the collagen triple helix must be glycine because the small side chain is the only one that fits at the helix interior). It serves as the primary inhibitory neurotransmitter in the spinal cord and brainstem (via glycine receptors), while also acting as an obligatory co-agonist for NMDA glutamate receptors throughout the brain. It is required for synthesis of glutathione (the body's master antioxidant), creatine (for energy metabolism), heme (for oxygen transport), bile acids (for fat digestion), and nucleotide bases (for DNA). It regulates one-carbon metabolism through the glycine cleavage system. It modulates immune function through glycine-gated chloride channels on macrophages and neutrophils. It stabilizes cell membranes, supports detoxification of many xenobiotics, and participates in the transamination reactions central to nitrogen metabolism. Given this biological breadth, it is perhaps not surprising that glycine supplementation has shown benefits across diverse clinical contexts: improved sleep quality (particularly subjective measures and early-night sleep), enhanced glutathione status in aging adults (the basis of the GlyNAC protocol), reduced symptoms in schizophrenia when combined with standard antipsychotics, improved glycemic control in type 2 diabetes, better outcomes after surgery and trauma, improved outcomes in chronic kidney disease, and potentially benefits for skin and joint health via collagen support. Dietary glycine comes primarily from collagen-containing foods—bone broth, slow-cooked meats with connective tissue, skin-on poultry and fish, gelatin desserts, and collagen supplements. Modern dietary patterns, which favor boneless skinless muscle meats over whole-animal consumption with connective tissue, deliver much less glycine than ancestral diets or traditional cuisines. A typical adult on a modern American diet consumes approximately 1.5-3 g glycine daily; Meléndez-Hevia and colleagues (PMID 19565307) calculated that the body's daily glycine requirement for collagen synthesis alone exceeds 10 g, and total requirement across all functions likely exceeds 15 g daily. This substantial gap is typically filled by endogenous synthesis, but synthetic capacity appears limited, particularly with aging and disease states. Supplementation of 3-10 g daily closes this gap conveniently and inexpensively. For users of BodyHackGuide, glycine represents one of the most underrated foundational supplements. The cost is trivial (pure glycine powder is among the cheapest supplements per gram), the taste is pleasantly sweet (making it easy to consume), the safety profile is excellent (human supplementation doses of 30+ g daily have been tested without significant adverse effects), and the evidence base spans sleep, glutathione/aging biomarkers, glycemic control, and connective tissue support. Common supplementation errors include: (1) assuming glycine effects will be rapid and dramatic—most benefits emerge over weeks of consistent use, (2) mixing up glycine with glucine or other unrelated compounds, (3) using inadequate doses (under 3 g daily often shows minimal effect on sleep), and (4) neglecting dietary sources of glycine in favor of supplementation when both are straightforward. This monograph addresses each of these issues with the specificity needed for informed self-experimentation. For related foundational support, see /compound/creatine, /compound/taurine, /compound/magnesium, and /compound/nac.

Also known as: Myo-inositol, D-chiro-inositol, DCI, Cyclohexanehexol, Vitamin B8 (historical, now disputed), meso-inositol, Inofolic, Inofolic Plus

Inositol is a naturally-occurring cyclic sugar alcohol (cyclohexanehexol) that functions as a critical structural component of cell membranes and a second-messenger precursor in intracellular signaling. Of the nine possible stereoisomers of inositol, only two — myo-inositol (myo-I) and D-chiro-inositol (DCI) — have significant biological activity in human physiology. These two isomers serve complementary roles: myo-inositol is the dominant form (~99% of tissue inositol), supports phosphatidylinositol signaling and serves as the precursor for inositol polyphosphates (IP3, IP4, etc.) that mediate insulin signaling and calcium release; D-chiro-inositol is a minor form (~1%) but has distinct insulin-related effects including roles in glycogen synthesis and lipid metabolism. The body synthesizes ~4 grams/day of inositol endogenously from glucose (primarily in kidneys) and obtains additional inositol from diet (fruits, beans, grains, nuts), so frank inositol deficiency is rare in healthy adults. However, supplemental inositol at pharmacologic doses (2-18g/day) produces substantial clinical effects that are used therapeutically across several domains including polycystic ovary syndrome (PCOS), insulin resistance and metabolic syndrome, anxiety and panic disorders, obsessive-compulsive disorder, depression, gestational diabetes prevention, and fertility/IVF tuning. The therapeutic history of inositol supplementation reflects parallel lines of research in psychiatry and reproductive endocrinology. In psychiatry, Levine et al. 1995-1997 and Fux et al. 1996, 1999 (PMIDs: 8780423, 10071466) established that high-dose oral myo-inositol (12-18g/day) produces anxiolytic effects equivalent to fluvoxamine (Luvox, an SSRI) for panic disorder and agoraphobia, and clinically meaningful improvement in obsessive-compulsive disorder symptoms. In reproductive endocrinology, Unfer and colleagues at the Unfer Institute in Rome established that myo-inositol supplementation (2-4g/day) improves ovulation, reduces hyperandrogenism, and improves pregnancy rates in women with PCOS — with meta-analyses consolidating these findings across 20+ trials (Unfer 2017 Int J Endocrinol PMID: 29081797, Laganà et al. 2018). In obstetrics, D'Anna and colleagues at the University of Messina demonstrated that myo-inositol 4g/day taken from early pregnancy reduces the incidence of gestational diabetes mellitus (GDM) in high-risk pregnancies by approximately 50% (D'Anna 2013, 2015 PMIDs: 23345600, 25829487) — findings with substantial public-health implications that have been incorporated into some international guidelines for GDM prevention. The 40:1 myo-inositol to D-chiro-inositol ratio has emerged as the dominant combination convention for PCOS and fertility applications, based on research by Nordio, Unfer, and colleagues showing that this ratio approximates the physiological ratio in follicular fluid and produces superior outcomes compared to either isomer alone or other ratios. This 40:1 ratio (typically 2000mg myo-I + 50mg DCI) is embodied in commercial products like Inofolic Plus and is the default recommendation for most reproductive applications. For non-reproductive applications (anxiety, OCD, depression, insulin resistance), myo-inositol alone at higher doses is more commonly used. Mechanistic understanding of inositol's clinical effects centers on its role in insulin signaling and phosphoinositide second messenger systems. Insulin binding to its receptor triggers a signaling cascade that includes generation of inositol phosphoglycans (IPGs) from glycosylphosphatidylinositol (GPI) lipids — myo-inositol-containing IPGs (MI-IPG) activate enzymes promoting glucose uptake and utilization, while D-chiro-inositol-containing IPGs (DCI-IPG) activate enzymes promoting glycogen synthesis. Insulin-resistant states — including PCOS (where ovarian insulin resistance is a core feature), obesity-related metabolic syndrome, and type 2 diabetes precursors — involve dysregulation of these IPG systems. Supplemental inositol appears to partially restore signaling efficiency, producing improvements in insulin sensitivity, reduced compensatory hyperinsulinemia, reduced ovarian androgen production, improved ovulation, and (in pregnancy) reduced gestational diabetes risk. In psychiatric applications, the mechanism is less clear but likely involves the phosphatidylinositol-linked neurotransmitter signaling systems (serotonin 5-HT2, muscarinic cholinergic, adrenergic-α1 receptors all signal partly through PI-PLC/IP3), with inositol depletion potentially implicated in lithium's mood-stabilizing mechanism (the "inositol depletion hypothesis" of Berridge). Regulatory status is complex: Inositol is classified as a dietary supplement in the United States and most countries, available without prescription. It is generally-recognized-as-safe (GRAS) at typical doses. In some European countries, pharmaceutical-grade inositol preparations are marketed for PCOS and gestational diabetes prevention with more formal regulatory oversight. It was historically designated "Vitamin B8" but this classification has been largely abandoned since humans synthesize sufficient inositol endogenously. The safety profile across extensive clinical use (including high-dose 12-18g/day psychiatric use and millions of pregnancies exposed to 4g/day for GDM prevention) is excellent. See also Metformin, Berberine, DHEA, Ashwagandha, Magnesium, N-acetylcysteine, Vitamin D, and Omega-3 for adjacent insulin-sensitizing, anti-inflammatory, and hormonal-support compounds commonly used in PCOS and metabolic tuning. This is educational content and not medical advice — while inositol is very safe, clinical applications (particularly in pregnancy, with psychotropic medications, or with diabetes medications) warrant physician-level guidance.

Bromantane is an atypical psychostimulant and anxiolytic developed in the 1980s at the Zakusov Institute of Pharmacology of the Russian Academy of Medical Sciences, originally created as an adaptogen for Soviet military and elite athletic use and later approved in Russia for the treatment of neurasthenic and asthenic disorders under the trade name Ladasten. Chemically it is N-(2-adamantyl)-N-(para-bromophenyl)amine, an adamantane derivative structurally related to amantadine and memantine but pharmacologically distinct from both. What makes Bromantane unusual and clinically interesting is that it acts simultaneously as a mild dopamine reuptake inhibitor and as an activator of tyrosine hydroxylase and aromatic L-amino acid decarboxylase gene expression in mesolimbic and mesocortical dopamine neurons, producing a gentle upregulation of endogenous dopamine synthesis rather than the forceful synaptic dopamine release characteristic of amphetamines or methylphenidate; alongside this dopaminergic effect it promotes neurosteroid synthesis particularly of allopregnanolone and related GABA-A positive modulators, which is thought to underlie its anxiolytic rather than anxiogenic profile and distinguishes it from conventional stimulants that typically produce dose-dependent anxiety. The clinical positioning in Russia has been for neurasthenia, asthenic depression, chronic fatigue states, post-infectious fatigue, and adaptation support during physical and cognitive stress, with multiple placebo-controlled and active-comparator trials published in Russian and occasionally English literature reporting benefits across fatigue, attention, mood, and sleep quality scales at daily doses typically in the 50-100 mg range for 2-6 week courses. Outside Russia Bromantane has never been approved for clinical use, is not controlled under most Western drug schedules because it predates modern scheduling and does not fit amphetamine or modafinil frameworks cleanly, and circulates primarily as a research chemical or grey-market nootropic with substantial user interest in biohacker communities. Its anti-doping status is important for athletes: WADA added Bromantane to the prohibited list in 1996 following the Atlanta Olympics when several Russian athletes tested positive, and it remains on the WADA S6 stimulants list; competitive athletes should absolutely avoid it regardless of the legal status in their jurisdiction. For a BodyHackGuide reader the honest framing is that Bromantane has a legitimate and interesting pharmacological profile, modest but real Russian clinical evidence for asthenic syndromes, a safety profile that appears favourable compared to classical stimulants in available data, and significant practical limitations around sourcing, anti-doping concerns, and absence of Western replication. Evidence-graded alternatives for fatigue, attention, and mood that a reader should consider alongside or instead of Bromantane include modafinil and armodafinil for wakefulness and attention (prescription in most jurisdictions), methylphenidate and amphetamine formulations for diagnosed ADHD under specialist care, SSRIs and SNRIs for depression and anxiety with comorbid fatigue, structured exercise and cardiorespiratory fitness development, sleep disorder workup and treatment where indicated, and addressing iron deficiency, vitamin D insufficiency, thyroid dysfunction, sleep apnoea, and depression as common reversible causes of chronic fatigue. Internal cross-links include noopept, selank, semax, bpc-157, modafinil, methylene-blue, nad, and sulbutiamine where those entries exist.

Also known as: Golden Root, Arctic Root, Roseroot, SHR-5, Rhodiolin, RhodioLife, Rosavins, Salidroside

Rhodiola rosea is a succulent perennial plant that grows in cold, high-altitude regions of the Arctic, Siberia, Scandinavia, Iceland, the Alps, the Pyrenees, and the Carpathian Mountains. Its golden-yellow rhizome has been used for over a thousand years as a tonic against fatigue, cold, and high-altitude exposure in Russian, Siberian, Scandinavian, and Tibetan traditional medicine. The Vikings reputedly consumed it to improve physical strength and endurance before long voyages, the Sherpa used it to tolerate thin mountain air, and Soviet cosmonauts, special forces, and Olympic athletes used it routinely from the 1960s forward as a state-sanctioned performance enhancer under the "adaptogen" research program led by Nikolai Lazarev and Israel Brekhman (PMID: 20378318). Where ashwagandha (withania somnifera) sits at the calming, parasympathetic-biased end of the adaptogen spectrum — lowering cortisol primarily at the adrenal level and producing mild sedation in many users — Rhodiola occupies the opposite pole: it is the stimulating, sympathetic-sparing, monoamine-modulating adaptogen, producing wakefulness, mental clarity, reduced fatigue, and mood elevation without the caffeinergic jitter of stimulants or the serotonergic side-effect burden of SSRIs. For chronically stressed, burned-out, or sub-depressed users — the classic "tired but wired," cortisol-dysregulated presentation — Rhodiola is often the more useful adaptogen than ashwagandha, and for many users the two are complementary: Rhodiola in the morning for energy and focus, ashwagandha in the evening for sleep onset and HPA-axis downshifting. The pharmacologically active constituents are the phenylpropanoid glycosides rosavin, rosin, and rosarin (collectively "rosavins," which are diagnostic for the species R. rosea and absent from most other Rhodiola species), the phenylethanoid glycoside salidroside (also called rhodioloside, present across multiple Rhodiola species and in low concentrations in Chinese willow bark Salix matsudana), p-tyrosol (the aglycone of salidroside and, as a side note, the same molecule absorbed from olive oil as a metabolite of oleuropein and hydroxytyrosol — an overlap worth noting if stacking polyphenols), and a set of monoterpene glycosides and flavonoids including rhodiolin and rhodalin. The clinical standard is "SHR-5," a Swedish Herbal Institute extract standardized to 3% rosavins and 1% salidroside in a roughly 3:1 rosavin-to-salidroside ratio that matches the naturally occurring ratio in wild R. rosea roots. Nearly every positive randomized trial in humans has used SHR-5 or extracts standardized to the same 3%/1% specification; extracts standardized to salidroside only, or to much higher salidroside concentrations (which often signals adulteration with other Rhodiola species such as R. crenulata or synthetic salidroside), do not necessarily reproduce SHR-5's effects. Commercial brands to prefer: NOW Rhodiola (SHR-5), Thorne Rhodiola Rosea (3%/1%), Gaia Herbs Rhodiola (3%/1%), Jarrow Formulas Arctic Root (SHR-5), Pure Encapsulations Rhodiola Rosea (3%/1%), and Life Extension Optimized Rhodiola (3%/1%, with added salidroside). The mechanism of action is fundamentally different from ashwagandha and sets Rhodiola apart from every other widely used adaptogen. Rosavins and salidroside modulate monoamine neurotransmission at multiple points: they inhibit monoamine oxidase A (MAO-A) and MAO-B activity, sparing serotonin, dopamine, and norepinephrine from enzymatic degradation (PMID: 19168123); they appear to inhibit catechol-O-methyltransferase (COMT) to a lesser degree; they modulate 5-HT1A and 5-HT2A receptor signaling centrally; and they cross the blood-brain barrier to act on hypothalamic and locus coeruleus monoamine systems directly. This MAO-inhibiting profile partially explains why Rhodiola produces antidepressant-like effects in a time-course (days, not weeks) faster than SSRIs and with much lower side-effect burden, while also explaining the small but real risk of serotonin syndrome when combined with prescription MAO-inhibitors or high-dose SSRIs. Beyond monoamines, salidroside activates AMP-activated protein kinase (AMPK), shifts cellular metabolism toward fat oxidation, and induces heat-shock protein 72 (HSP72) via a nuclear factor-kappa B (NF-κB) and stress-activated JNK pathway that Alexander Panossian's laboratory group at the Swedish Herbal Institute demonstrated across cell, rodent, and human studies (PMID: 20378318, 22265417). The HSP72 induction mechanism is the molecular correlate of the "adaptogen" concept proposed by Lazarev: a compound that raises cellular stress resistance non-specifically by priming the heat-shock response, so that subsequent stressors (thermal, oxidative, inflammatory, cognitive) are better tolerated. Clinically, the evidence base is strongest for three indications: (1) stress-related fatigue and burnout, where multiple randomized placebo-controlled trials (Olsson 2009, Edwards 2012, Cropley 2015, Kasper 2019 meta-analysis) consistently show reductions in fatigue scores, subjective stress, and burnout symptoms after 4-12 weeks at 200-400 mg/day of SHR-5 (PMID: 18307390, 22228617, 25172313, 31244915); (2) mild-to-moderate depression, where Darbinyan 2007 and Mao 2015 (Penn Integrative Medicine) demonstrated efficacy comparable to low-dose sertraline with far fewer side effects (PMID: 22228617, 26640839); and (3) short-term cognitive performance under fatigue, demonstrated in the classic Spasov 2000 student exam trial (101 medical students, single dose improved mental capacity by 8-30% across cognitive subtests, PMID: 10839209) and the Darbinyan 2000 night-shift physician trial (56 physicians, 170 mg/day for 2 weeks reduced mental fatigue 20% on complex perceptual tasks, PMID: 11081987). Effects on physical endurance are more mixed: De Bock 2004 showed improved time-to-exhaustion on cycle ergometer after a single 200 mg dose (PMID: 15256690), but multi-dose chronic-exercise trials have been less consistent, and Rhodiola appears to help most when fatigue or sleep deprivation is limiting performance rather than in rested, well-trained athletes. This entry is the most complete public synthesis of Rhodiola rosea pharmacology, clinical evidence, dosing strategy, and stacking logic currently available. For context on adaptogen comparison, see ashwagandha, bacopa monnieri, holy basil, and schisandra. For complementary stress-resilience nutrients, see magnesium, l-theanine, and taurine. For mood-adjacent compounds, see saffron, sam-e, and saffron. For athletic performance stacks, see creatine, beta-alanine, and citrulline.

Also known as: Schisandra chinensis, Schizandra, Wu Wei Zi, Five-Flavor Fruit, Five-Flavor Berry, Omija, Magnolia Vine, Chinese Magnolia Vine, Schisandrin, Gomisin, Northern Schisandra

Schisandra (scientific name Schisandra chinensis; called wu wei zi in Chinese, literally "five-flavor fruit" — referring to the berry's unique property of exhibiting all five basic tastes simultaneously: sweet, sour, salty, bitter, and pungent/spicy — omija in Korean, and gomishi in Japanese) is a deciduous woody vine native to the cold temperate forests of Northeast China, Korea, eastern Russia (particularly the Russian Far East, Primorsky region, and parts of Siberia), and Japan, producing distinctive bright-red berries in dense clusters during late summer and autumn. It belongs to the family Schisandraceae (sometimes placed in Magnoliaceae in older classification), and a related species Schisandra sphenanthera (southern schisandra) is also medicinally used in southern China, though S. chinensis (northern schisandra) is more studied and commercially important. Schisandra has been documented in Chinese materia medica for over 2,000 years, classified in the Shen Nong Ben Cao Jing (the Divine Farmer's Classic of Materia Medica, ~200 BCE) as a superior herb category member — the same elite classification given to ginseng and reishi — with applications for calming the spirit, nourishing the kidneys, astringent tonification, liver protection, and promoting longevity. Schisandra occupies a particularly interesting position in adaptogen research because it served as one of the central herbs in the Soviet/Russian adaptogen research program from the 1940s-1990s, alongside Siberian ginseng (Eleuthero) and Rhodiola rosea. Russian researchers — notably Israel Brekhman (who coined the term "adaptogen" and developed much of the modern scientific framework), Nikolai Lazarev (his mentor and collaborator), Alexander Panossian (who continues this research tradition into the 21st century), and the Institute of Biologically Active Substances (Russian Academy of Sciences, Vladivostok) — conducted extensive research on schisandra's effects on physical and mental performance, stress tolerance, fatigue reduction, and longevity during the Cold War era. Schisandra was used extensively by Soviet soldiers, cosmonauts, Olympic athletes, and industrial workers for cognitive and physical performance enhancement. Much of this research was published in Russian-language journals and remained largely unknown in the West until recent decades. Alexander Panossian has continued to publish Western-language research on schisandra and other traditional adaptogens, making this body of work more accessible. The primary bioactive compounds in schisandra are a family of unique dibenzocyclooctadiene lignans (a structural class mostly unique to this plant family), including schisandrin A, B, C, and D; schizandrol A and B; schisantherin A, B, and C; gomisin A, B, C, J, and N; wuweizisu A, B, and C; and approximately 30+ related compounds. The total lignan content typically ranges from 2-7% in dried berries, and these compounds drive the majority of the pharmacological effects. Additionally, schisandra contains polysaccharides, essential oils (responsible for the aroma and some tastes), organic acids (citric, malic, tartaric — contributing to the sour component of the "five flavors"), vitamin C, carotenoids, volatile oils containing terpenes, and minor alkaloids. The distinctive "five flavors" arise from different compound classes: sweet from sugars in the pulp, sour from organic acids, salty from mineral content, bitter from lignans and related compounds, and pungent from volatile oils and the seeds. Traditional Chinese medicine assigns each flavor to specific organ system affinities, making schisandra unusually broad-acting in the TCM framework (affecting heart, liver, kidney, lung, and spleen). The proposed clinical applications of schisandra span: (1) hepatoprotection and liver disease — perhaps the strongest evidence base, with research in chronic hepatitis B and C, non-alcoholic fatty liver disease (NAFLD), and drug/toxin-induced hepatotoxicity; schisandrin B is particularly notable for its hepatoprotective effects and has been developed into pharmaceutical products in China; (2) cognitive function and mental performance — improvements in attention, memory, and reaction time, with research in healthy adults, fatigued populations, and neurodegenerative models; (3) stress adaptation — classical adaptogen effects on cortisol, HPA-axis, and resilience to physical and psychological stressors; (4) physical performance — aerobic and anaerobic exercise capacity, with Russian Olympic-era research heritage; (5) cardiovascular effects — modest blood pressure support, possible antiarrhythmic properties, improvements in cardiac function markers; (6) perimenopausal and menopausal symptoms — emerging evidence for hot flashes, sweating, and mood effects; (7) respiratory conditions — traditional use for cough and asthma; and (8) general wellbeing and longevity — the traditional indication. The human clinical evidence is moderate — stronger than for many folk remedies but weaker than for pharmaceutical treatments in any specific indication. Panossian et al. 2009 (Phytomedicine, PMID 19264458) — a randomized controlled trial of ADAPT-232 (a combination of schisandra, rhodiola, and eleuthero) in 108 tired patients over 4 weeks demonstrated significant improvements in attention, accuracy, and speed of complex cognitive tasks. While this tests a combination product rather than schisandra alone, it represents well-designed Panossian-tradition adaptogen research. Panossian and Wikman 2008 (Phytomedicine, PMID 18515051) — review of schisandra clinical pharmacology including studies on fatigue, cognitive function, and physical performance. The review synthesizes Russian-era and modern research, concluding that schisandra has "adaptogenic properties increasing resistance to a wide range of stressors of physical, chemical, and biological origin." Hancke et al. 1996 and Aslanyan et al. 2010 — Russian research on athletic performance showing improvements in time-to-exhaustion, oxygen utilization, and recovery in athletes supplemented with schisandra extracts. Methodology in some of this research doesn't meet modern Western standards but the consistent direction of benefit across multiple trials is suggestive. Chinese hepatitis research — multiple studies (mostly Chinese-language) have examined schisandrin and schisandra extracts in chronic hepatitis B and C, with reported improvements in liver enzyme levels (ALT, AST), liver function markers, and some viral parameters. A 2013 systematic review of Chinese-language schisandra hepatitis research concluded that the evidence is suggestive but methodology often falls short of Western standards. Park et al. 2012 (Menopause, PMID 22781784) — small trial of schisandra fruit extract in 36 perimenopausal women with vasomotor symptoms. Results showed reductions in hot flash frequency and severity compared with placebo, plus improvements in heart rate variability. While a small trial, this provided preliminary support for schisandra in menopausal support. Aslanyan et al. 2010 (Phytotherapy Research) and related Panossian-lab trials have examined schisandra in combination with other adaptogens for cognitive performance, mental fatigue, and stress resilience — generally with positive but modest effects. Where does schisandra fit in the therapeutic landscape? For chronic liver conditions, schisandra is an interesting adjunctive option (alongside standard care) given the mechanistic plausibility (Nrf2 activation, CYP modulation, direct antifibrotic effects), though it should NOT replace evidence-based hepatology treatment (entecavir/tenofovir for HBV, direct-acting antivirals for HCV, lifestyle management for NAFLD, appropriate monitoring). For general adaptogenic use, cognitive/physical performance, and stress resilience, schisandra is a reasonable natural option with moderate evidence. For menopausal symptom management, preliminary evidence supports consideration as part of a broader approach. It is NOT a substitute for evidence-based medications for any specific disease, and users should understand that its effects, while real, are modest. It sits honestly alongside Rhodiola rosea, Eleuthero, Ashwagandha, Panax ginseng, and Reishi as one of the classical adaptogens, with the distinctive features of its five-flavor pharmacology, hepatoprotective emphasis, and deep Russian research heritage. Safety is generally excellent at typical doses, with the significant caveat that schisandra is a notable inducer of cytochrome P450 enzymes (particularly CYP3A4) and also inhibits P-glycoprotein — making drug interactions an important consideration in those on pharmaceutical medications. Schisandra should be used cautiously by anyone on narrow-therapeutic-index drugs (warfarin, digoxin, tacrolimus, cyclosporine, certain antiepileptics, chemotherapies).

Also known as: Holy Basil, Ocimum tenuiflorum, Ocimum sanctum, Tulasi, Queen of Herbs, Mother Medicine of Nature, Rama Tulsi, Krishna Tulsi, Vana Tulsi, Sacred Basil, Indian Basil, Manjari, Kala Tulsi

Tulsi (scientific name Ocimum tenuiflorum, formerly classified as Ocimum sanctum; called tulasi in Sanskrit and most Indian languages, holy basil or sacred basil in Western herbalism, and kala tulsi or manjari for specific varieties) is a perennial aromatic herb in the Lamiaceae family (mint family), native to the Indian subcontinent but now cultivated throughout tropical and subtropical regions worldwide. Unlike culinary sweet basil (Ocimum basilicum) — used in Italian cuisine and pesto — tulsi is a related but distinctly different plant species, with strong clove-like, slightly peppery aromatic character from its high eugenol content and a genuine medicinal tradition spanning thousands of years. The plant reaches 30-60 cm in height with hairy stems and fragrant green or purple leaves, producing small pink-purple flowers in terminal spikes. Tulsi holds an exceptional position in Indian culture, spirituality, and traditional medicine that is genuinely unique among adaptogens. In Hindu tradition, tulsi is considered a manifestation of the goddess Lakshmi (consort of Vishnu), is planted in the courtyard of millions of Hindu homes, is offered in daily worship rituals, and is considered a sacred plant with protective properties. Ayurvedic texts refer to tulsi as "Queen of Herbs" (Osadhi-rani), "Incomparable One" (Apet-rakshasi), and "Mother Medicine of Nature" — titles reserved for herbs of particular significance. The Charaka Samhita (~400 BCE) and Sushruta Samhita (~600 BCE), the foundational Ayurvedic texts, both reference tulsi extensively for stress reduction, respiratory conditions, fever, and general rejuvenation. Tulsi is classified as a rasayana — a rejuvenative herb promoting longevity and vitality — and as a tridoshic herb that balances all three Ayurvedic constitutional types (vata, pitta, kapha), though with a particular affinity for reducing kapha and calming vata. Three major chemotypes (botanical varieties) are distinguished in tulsi and have somewhat different phytochemical profiles and traditional uses: (1) Rama tulsi (Sri tulsi) — the green-leaved, lighter-colored variety with sweeter, less pungent flavor; dominant in eugenol and traditionally used for general wellness and women's health; (2) Krishna tulsi (Shyama tulsi) — purple-leaved, with more intense aromatic properties and higher eugenol content; considered most potent medicinally and traditionally used for respiratory conditions, stress, and infection; (3) Vana tulsi (wild forest tulsi, Ocimum gratissimum) — a related species found growing wild in forests; typically tall, with different phytochemistry emphasizing thymol and other components. Commercial tulsi products may contain one specific chemotype or combinations of all three. The famous "Tulsi Sleep" or "Tulsi Restful" products from Organic India and similar companies typically use Krishna + Rama + Vana combinations. The primary bioactive compounds in tulsi span multiple chemical classes: phenolic compounds (eugenol — often the dominant aromatic compound at 20-70% of essential oil content, carvacrol, methyl eugenol); triterpenoid compounds (ursolic acid — a prominent anti-inflammatory triterpene, oleanolic acid, β-caryophyllene); flavonoids (apigenin, luteolin, vicenin, orientin); phenolic acids (rosmarinic acid — shared with rosemary and similar herbs, caffeic acid); lignans (ocimumosides A and B — unique tulsi-specific compounds identified for their cortisol-modulating effects); essential oils containing approximately 30-70 identified compounds depending on variety and growing conditions. The dominant pharmacologic "driver" compounds vary by indication — eugenol for antimicrobial and analgesic effects, ursolic acid and rosmarinic acid for anti-inflammatory and antioxidant effects, ocimumosides and related compounds for adaptogenic/cortisol-modulating effects. The proposed clinical applications of tulsi span: (1) stress reduction and anxiety modulation — perhaps the best-evidenced modern application with multiple RCTs showing cortisol reduction and stress symptom improvement; (2) metabolic health — promising research in type 2 diabetes, lipid profiles, and metabolic syndrome with multiple human trials; (3) respiratory health — traditional primary use for cough, asthma, bronchitis, upper respiratory infections with growing modern evidence; (4) immune support and infection — antimicrobial, antiviral, antifungal activity in vitro and traditional use during infections; (5) cognitive function — attention, memory, and mood effects; (6) cardiovascular effects — mild antihypertensive, antiplatelet, and lipid-modulating effects; (7) hepatoprotection — protective effects in preclinical hepatotoxicity models; (8) radioprotection — emerging research on radiation protection for cancer patients; (9) adaptogen for general wellness — Ayurvedic traditional use as rasayana; and (10) women's health — traditional use for menstrual disorders, menopause, and fertility (though evidence here is weakest). Human clinical evidence has grown substantially over the past 2 decades. Key trials: Bhattacharyya et al. 2008 (Nepal Medical College Journal) — RCT of 150 subjects with generalized stress given tulsi extract 1200mg/day for 6 weeks showed significant reductions in stress symptoms, forgetfulness, sexual problems, exhaustion, and sleep problems compared with placebo. Saxena et al. 2012 (Evidence-Based Complementary and Alternative Medicine, PMID 22438876) — RCT of 35 adults with generalized anxiety disorder given tulsi extract 500mg twice daily for 60 days showed significant improvements in Hamilton Anxiety scale, depression, and stress scores. Sampath et al. 2008 — RCT examining tulsi in metabolic syndrome showed improvements in blood glucose, lipid profile, and blood pressure. Jamshidi and Cohen 2017 (Evidence-Based Complementary and Alternative Medicine, PMID 28400848) — systematic review of 24 clinical trials concluded that tulsi shows clinical promise particularly for metabolic disorders, stress, cognitive function, and immune health, though noted heterogeneity in trial quality. Chatterjee et al. 2013 — demonstrated improvements in reaction time and short-term memory with tulsi supplementation in healthy subjects. Agrawal et al. 1996 (diabetes), Rai et al. 1997 (diabetes), Mondal et al. 2011 (immune) — each showing specific improvements in respective endpoints. Saxena et al. 2007 — demonstrated benefits in stress-related respiratory symptoms. Where does tulsi fit in the therapeutic landscape? As an adaptogen, tulsi offers a distinctive profile: (1) milder and more broad-spectrum than Rhodiola rosea or Panax ginseng; (2) more grounding/centering and less activating than Eleuthero; (3) with distinctive anti-inflammatory and metabolic effects not prominent in other classical adaptogens; (4) with a cultural/spiritual dimension unique among adaptogens; and (5) with emerging evidence specifically for metabolic syndrome and anxiety disorders. It pairs well with Ashwagandha (the other major Ayurvedic adaptogen), Bacopa monnieri (for cognitive support), Turmeric (shared anti-inflammatory actions), and Holy Basil is often positioned alongside Shilajit in complete Ayurvedic rejuvenation protocols. Tulsi is NOT primarily a libido or testosterone herb (unlike Tongkat Ali or Panax ginseng), NOT primarily a sleep herb (unlike Ashwagandha evening dosing or Reishi), and NOT primarily a performance enhancer (unlike rhodiola). Its sweet spot is daily stress resilience with metabolic and immune benefits, taken as a gentle tonic. Safety is excellent for most users at culinary and therapeutic doses, with tulsi having been consumed as food and medicine by hundreds of millions of people for thousands of years. Modern formal toxicology confirms low toxicity. Key considerations include: mild antiplatelet effects from eugenol content (caution with anticoagulants), potential effects on thyroid hormones and blood glucose (generally favorable but requires monitoring in treated patients), potential male fertility effects at very high doses (probably not clinically relevant at typical doses), and standard caution in pregnancy despite traditional use.

Also known as: Eleutherococcus senticosus, Siberian Ginseng, Ci Wu Jia, Devil's Shrub, Touch-Me-Not, Wild Pepper, Acanthopanax senticosus, Eleutherococcus, Russian Root, Eleutheroside

Eleuthero (scientific name Eleutherococcus senticosus, formerly classified as Acanthopanax senticosus; called ci wu jia in Chinese, siberian ginseng in Western herbalism — though this common name is problematic and technically inaccurate as eleuthero is NOT in the Panax genus of true ginsengs — devil's shrub or touch-me-not in some English sources, and russian root reflecting its extensive Russian use) is a deciduous shrub in the Araliaceae family (ivy family), growing 2-3 meters tall with spiny stems, native to the cold temperate forests of the Russian Far East (Primorsky and Khabarovsk regions, Amur and Ussuri river basins), Northeast China, Korea, and Hokkaido Japan. The medicinal portion is primarily the root and rhizome, though stem bark and leaves have also been used. The plant is armed with prominent thorns (hence "devil's shrub"), grows in well-drained mixed forests, and has been harvested from wild populations for centuries and more recently cultivated. Eleuthero occupies a uniquely foundational place in adaptogen science because it was the primary research plant used by Nikolai Lazarev and Israel Brekhman to develop and validate the entire modern concept of "adaptogens" from the 1940s through 1970s. Brekhman, working at the Institute of Biologically Active Substances (Russian Academy of Sciences) in Vladivostok, conducted thousands of studies examining eleuthero's effects on physical and mental performance, stress tolerance, immune function, and various disease states. The term "adaptogen" itself, coined by Lazarev in 1947 and developed by Brekhman, was initially defined through eleuthero's demonstrated properties: (1) non-specific increase in resistance to a wide range of physical, chemical, and biological stressors; (2) normalizing influence regardless of the direction of pathological change; and (3) innocuous, non-toxic effect on normal physiological function. Eleuthero was used extensively by Soviet cosmonauts (including on long-duration Mir station missions), Soviet Olympic athletes (where its use predated and influenced the later IOC debates about ergogenic aids), Soviet soldiers (for cold resistance and performance), industrial workers (for shift work and fatigue), polar expedition members, and deep-sea divers. This provided an unusually extensive "real-world" database of eleuthero use under extreme conditions. Despite this heritage, eleuthero's reputation has been somewhat clouded by two factors: (1) the misleading "Siberian ginseng" name suggested equivalence to true Panax ginseng, leading to confusion and eventual regulatory action — the US FDA in 2002 required that eleuthero products no longer be labeled "ginseng" to distinguish them from true ginseng; and (2) widespread adulteration issues, particularly with Periploca sepium (Chinese silk vine, a plant from an entirely different family — Apocynaceae — containing cardiac glycosides and NOT an adaptogen). Multiple cases of eleuthero adulteration have been documented, and some clinical trials have used inadequately authenticated material. These issues make standardization and quality sourcing critical when using eleuthero. The primary bioactive compounds in eleuthero are a family of compounds called eleutherosides, labeled A through M, which are structurally diverse — NOT a single chemical class but rather a group of compounds with different structures that co-occur in the plant. The most important are: eleutheroside B (syringin, a phenylpropanoid glycoside), eleutheroside E (a lignan glycoside structurally unrelated to eleutheroside B), eleutherosides I, K, L, M (triterpenoid saponins structurally similar to panaxosides of true ginseng but differently substituted), and chlorogenic acid derivatives. Additional compounds include isofraxidin (a coumarin), sesamin (a lignan also found in sesame), β-sitosterol, various polysaccharides with immune-modulating activity, and minor flavonoids. The commonly cited "eleutherosides B+E" standardization marker reflects the research tradition of using these two as primary pharmacologic markers, though whole-extract pharmacology involves the full spectrum of compounds. Different plant parts contain different compound profiles — root/rhizome is the traditional medicinal material and has the most complete profile, while stem bark (sometimes used) has a different but overlapping composition. The proposed clinical applications of eleuthero span: (1) stress resilience and HPA-axis support — the classical adaptogen indication; (2) physical performance and endurance — with extensive Russian sports medicine research; (3) mental performance under fatigue — attention, reaction time, mental stamina; (4) immune support — modest evidence for increased NK cell activity and modulation of T-lymphocyte populations; (5) convalescence and recovery — traditional use during recovery from illness; (6) chronic fatigue syndrome — with specific clinical research; (7) shift work adaptation — particularly Russian research in industrial and medical settings; (8) herpes simplex management — small study showing reduced outbreak frequency; (9) cardiovascular adaptation — effects on cardiac response to acute stressors; (10) cognitive support in elderly — with Cicero 2004 trial showing improved cognition; and (11) general wellbeing and vitality tonic. The human clinical evidence is substantial in quantity — thousands of Russian studies plus growing Western research — though quality is heterogeneous, with older Russian studies often not meeting modern Western methodological standards. Key Western-standard trials include: Cicero et al. 2004 (Archives of Gerontology and Geriatrics, PMID 14599709) — RCT in 20 elderly subjects showing improvements in quality of life, cognitive function (attention, short-term memory), and social functioning over 4-8 weeks of eleuthero supplementation. Facchinetti et al. 2002 — demonstrated attenuation of cardiovascular response to mental stress testing in humans given eleuthero. Asano et al. 1986 (Planta Medica, PMID 3725924) — eleuthero extract improved maximal work capacity and VO2 max in trained athletes; an early Japanese replication of Russian findings. Kuo et al. 2010 — improvements in endurance cycling time-to-exhaustion with eleuthero. Williams 1994, 1995 — showed NO ergogenic/stimulant effects above baseline in normal-state athletes, supporting the "normalizing" adaptogen concept rather than stimulant effects. Hartz et al. 2004 (Psychological Medicine, PMID 14713161) — 96 chronic fatigue syndrome patients; eleuthero did NOT show significant benefit vs. placebo for the primary endpoint (though subgroups of less-severe fatigue showed some improvement) — an important null-or-modest finding in chronic fatigue. Freye et al. 2001 — improvements in cognitive function and wellbeing in shift workers. Bohn et al. 1987 — lymphocyte subpopulation changes demonstrating immune modulation. Williams et al. 1987 — early evaluation of eleuthero for herpes. Where does eleuthero fit in the therapeutic landscape? It is a milder adaptogen than Rhodiola rosea (less stimulating, lower fatigue-reversal magnitude), Panax ginseng (less overtly tonifying, lower testosterone/libido effects), or Ashwagandha (less sedating, lower acute anxiolytic effect). Its strengths are: (1) the deepest scientific heritage among adaptogens, with decades of consistent findings across varied populations; (2) an excellent safety profile at typical doses; (3) compatibility with stacking (minimal drug interactions compared with Schisandra or Panax ginseng); (4) a broad but modest effect profile suitable for baseline adaptogen foundation; and (5) strong evidence in specific niches like shift work, convalescence, and endurance. Its limitations are: (1) effects are modest and often require multi-week timelines to fully manifest; (2) quality/adulteration issues have historically complicated research interpretation; and (3) it is generally less "felt" than more pharmacologically active herbs (a feature for long-term use but a limitation if seeking acute effects). Eleuthero forms the third component of the ADAPT-232 classical Russian adaptogen formula (eleuthero + Rhodiola rosea + Schisandra), which has been tested in multiple Panossian-lab trials. Safety is excellent at typical doses, with rare side effects limited to mild insomnia at higher doses, rare mild hypertension, caution in bipolar disorder (theoretical risk of mania), and a notable interaction consideration with digoxin (eleuthero may cause false-positive digoxin assays in blood tests — a laboratory interference rather than a pharmacological interaction, but clinically important). Quality sourcing is critical due to adulteration concerns.

Also known as: Crataegus, Crataegus monogyna, Crataegus laevigata, Crataegus oxyacantha, Crataegus pinnatifida, Shan Zha, May Tree, Whitethorn, Hagthorn, Quickthorn, Mayblossom

Hawthorn (Crataegus species — principally Crataegus monogyna, C. laevigata, C. pinnatifida, and C. cuneata) is the most extensively studied cardiovascular botanical in the Western pharmacopoeia and one of very few herbs with formal pharmaceutical regulatory approval in Europe for a specific cardiovascular indication. In Germany and several other European countries, standardized hawthorn extracts — most notably WS 1442, marketed under the name Crataegutt — are approved by Commission E and BfArM for the symptomatic treatment of mild heart failure corresponding to NYHA (New York Heart Association) functional classes I and II. This is a notable regulatory position for a botanical: hawthorn is not an adjuvant or a wellness supplement in the European context but a registered drug used alongside or as an alternative to pharmaceutical therapy in early heart failure, with a body of controlled trial evidence stretching back to the 1980s. The plant itself is a thorny, small-to-medium tree or large shrub in the Rosaceae family (the rose family, which it shares with apples, pears, roses, and almonds), native across the temperate zones of the Northern Hemisphere, with the European species forming dense hedgerows in the British Isles, Ireland, and continental Europe, and the Chinese species producing small, sweet-sour, red-orange fruits that are a staple in Traditional Chinese Medicine as Shan Zha — used primarily for digestive stagnation and food accumulation, and secondarily for cardiovascular support. The pharmacologically active constituents cluster in three main groups: oligomeric proanthocyanidins (OPCs), which are the dominant antioxidant constituents and the primary component standardized in the premium European extracts; flavonoids including hyperoside, vitexin, vitexin-2-O-rhamnoside, rutin, quercetin, and luteolin, which contribute to vasodilatory, inotropic, and anti-arrhythmic effects; and pentacyclic triterpenes like ursolic acid, oleanolic acid, and crataegolic acid, which modulate ion channels in cardiac myocytes. The leaves and flowers together carry the highest concentration of flavonoids and are the standard source for European pharmaceutical extracts; the berries carry higher concentrations of OPCs and are preferred in American and Chinese herbal traditions. Many of the best commercial products combine both leaf-flower and berry material to capture the full phytochemical spectrum. Mechanistically, hawthorn is unique among cardiovascular botanicals because it produces a combination of mild positive inotropy (increased cardiac contractility) through a cAMP-independent mechanism — which means it strengthens contraction without the arrhythmogenic risk that accompanies digitalis or beta-agonists — alongside mild coronary and peripheral vasodilation through endothelial nitric oxide release and potassium channel modulation, along with mild anti-arrhythmic activity through prolongation of the refractory period in cardiac myocytes. The net hemodynamic effect is improved cardiac output at lower myocardial oxygen demand, which is precisely what a failing or ischemic heart needs. Clinically, the strongest evidence base is in NYHA Class I-II heart failure, where controlled trials have shown improved exercise tolerance, reduced shortness of breath and fatigue, improved quality-of-life scores, and small but measurable improvements in echocardiographic parameters. The SPICE trial (Holubarsch 2008, PMID 18191779) randomized 2,681 patients with NYHA II-III heart failure on background standard therapy to WS 1442 or placebo; the primary composite cardiovascular endpoint did not reach significance overall, but subgroup analyses suggested benefit in patients with preserved systolic function and reduction in sudden cardiac death. A Cochrane-style systematic review by Pittler and colleagues pooling 14 controlled trials found consistent improvements in exercise tolerance and symptoms across the evidence base. Beyond heart failure, hawthorn has smaller but credible evidence for mild hypertension, stable angina adjunctive support, and functional arrhythmia management. The herb is distinctly not a substitute for evidence-based pharmaceutical heart failure therapy — ACE inhibitors, angiotensin receptor-neprilysin inhibitors, beta blockers, SGLT2 inhibitors, mineralocorticoid receptor antagonists, and device therapy have transformed the prognosis of heart failure over the past thirty years, and hawthorn should be viewed as a complement to, not a replacement for, that foundation. But for patients with mild, stable symptoms, patients who cannot tolerate full pharmaceutical dosing, or patients who wish to improve cardiac resilience alongside standard therapy, standardized hawthorn is one of the few supplements with a genuinely rigorous evidence base. The typical clinical dose of WS 1442 is 900 mg/day divided into two or three doses (equivalent to 160-180 mg of the 18-20% OPC standardized extract); for crude leaf-flower or berry extracts, 900-1800 mg/day of well-standardized product is a reasonable range. Onset of effect is slow — 4-8 weeks for initial improvements in exercise tolerance and 6-12 weeks for stable effects on symptoms. Hawthorn is extraordinarily well tolerated, with the main side effects being mild gastrointestinal upset, occasional headache, and very rarely mild palpitations at the start of therapy. The most important clinical caveat is potential potentiation of digitalis (digoxin) and, more broadly, additive effects with antihypertensive medications — patients on heart failure or hypertension drug therapy should introduce hawthorn in consultation with their cardiologist or primary care provider, with appropriate monitoring of blood pressure, heart rate, and renal function as indicated.

Also known as: EDR

Pinealon is a synthetic tripeptide — glutamyl-aspartyl-arginine (Glu-Asp-Arg, or EDR) — developed by the St Petersburg Institute of Bioregulation and Gerontology (IBG) under the leadership of Professor Vladimir Khavinson, the dominant figure in what is collectively known as the "Russian short-peptide bioregulator" school of research. Pinealon was designed as a peptide analog of signaling molecules found in natural extracts of the pineal gland, specifically a class of bioactive compounds that Khavinson's group began isolating and characterizing in the late 1980s as "cytomedins" — short peptides extracted from specific animal tissues and claimed to carry tissue-specific regulatory signals back to the corresponding tissue type. The Khavinson framework is as follows: the pineal gland, like other endocrine and parenchymal organs, contains short regulatory peptides that are involved in cell differentiation, gene expression regulation, and tissue homeostasis. When these natural peptides are purified, sequenced, and synthetic analogs are produced (the short-peptide analogs being the most studied), the synthetic peptides retain the ability to influence the same tissue from which they were derived. Pinealon, as the pineal-derived tripeptide bioregulator, is claimed to act on neural tissue — particularly the brain — to support neuroprotection, cognitive function, circadian regulation, and protection against age-related neurodegeneration. A substantial body of Russian-language clinical and preclinical literature supports these claims, going back to the 1990s and continuing through 2026. The work has been led by Khavinson and his collaborators at the Mechnikov North-Western State Medical University in St Petersburg, published in Russian medical journals (Uspekhi Gerontologii, Bulletin of Experimental Biology and Medicine) and selected Western journals (Neuroendocrinology Letters, Biogerontology). Outside Russia, Pinealon is part of a broader group of short-peptide bioregulators that includes Epitalon, Thymogen, Thymalin, Vilon, Livagen, and others — each claimed to be organ-specific based on the source tissue of the original natural peptide extract. The Western biomedical community has given Khavinson's work a mixed reception. On the positive side, the theoretical framework — that short peptides could function as tissue-specific gene-expression modulators — is scientifically coherent, and a subset of the claims (particularly around Epitalon and telomere biology) has attracted genuine interest and some independent replication. On the skeptical side, the clinical datasets are predominantly Russian, the independent replication of the most dramatic outcomes is thin, the peptides have never been through standard Western regulatory approval processes, and the commercial availability in Russia through the "Cytogen" brand (Cytomed) and various gerontology clinics has driven a significant body-hacking export market without corresponding Western clinical validation. This entry takes the honest position that Pinealon — and the broader Russian short-peptide bioregulator category — represents a plausible mechanism of action with real Russian clinical use, limited Western replication, and a research-grade user experience outside Russia. It is not FDA-approved, not widely available through Western prescription pharmacies, and carries the full research-chemical status in most Western jurisdictions. Users engaging with Pinealon are effectively trusting Khavinson's lab and its affiliated clinical collaborators, without the standard Western regulatory and replication infrastructure. For readers exploring the Khavinson peptide space, see also Epitalon, Thymogen, Cartalax, Vilon, and related entries. For comparison with other short-peptide neuroprotective compounds, see Cerebrolysin (a larger neuropeptide preparation), Semax (Russian ACTH-derived peptide), and Selank.

Also known as: Ala-Glu-Asp-Gly, Cardiac Bioregulator, Cortexin (related), Khavinson Cardiac Peptide

Cortagen is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) from the Khavinson bioregulator family developed at the St. Petersburg Institute of Bioregulation and Gerontology. It is organ-targeted to cardiac and coronary tissue, studied for cardiac function preservation and coronary artery health in aging and post-ischemic models. Like other Khavinson bioregulators (Pinealon, Bronchogen, Cartalax, Epithalon), Cortagen is proposed to act via direct gene-regulatory mechanisms in target tissue rather than classical receptor-ligand signaling. Russian clinical literature includes use in elderly patients with cardiovascular disease and post-myocardial infarction recovery. It is distinct from the cortex-targeting Khavinson peptide Cortexin.